December 3, 2019

OWP Pharmaceuticals Announces a Second IND Approval and Patent Application: The First-Ever Liquid Oral Suspension Formulation of Lamotrigine for the Treatment of Epilepsy and Bipolar Disorder

Share this press release:

Document loads below this notification.

Additional Press Releases

January 12, 2026 / Press Release

OWP Pharmaceuticals Announces Commercial Product Availability of SUBVENITE® (lamotrigine) Oral Suspension in U.S. Market

September 18, 2025 / Press Release

OWP Pharmaceuticals Announces FDA Approval of SUBVENITE® (lamotrigine) Oral Suspension

May 20, 2024 / Press Release

OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension